Business Development

LTS is the global market leader in the development and manufacture of transdermal systems LTS TTS and oral thin films LTS OTF. LTS continued its successful development once again in 2019 and remains on course for further growth.

In 2019, LTS once again beat its previous records in terms of turnover, financial result, equity capital and liquidity. In line with the corporate strategy, the necessary investments into the expansion of structural and technical facilities were made.

LTS conducted multiple active cooperation projects in 2019 with a large number of different partner companies from the pharmaceutical industry. These projects covered transdermal therapeutic systems (TTS), oral thin films (OTF) as well as Micro Array Patches (MAP).

The continuous evolution of existing LTS TTS and LTS OTF solutions, as well as innovations in new technology platforms such as microinvasive, transdermal systems or needle-free injection systems, are based on significant therapeutic requirements and market potential.

  • > 1.100 Employees

  • 300 Mio. € Turnover

  • 770+ Mio. Systems produced in 2018

  • 24,5 Mio. € Investments

  • 8,4 % R&D expenditures (of turnover)

  • owner of more than 300 patent families